Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04640077 · ClinicalTrials.gov registry record · Phase 2
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
A Phase 2 study of Alzheimer Disease and Dementia, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT04640077 is a Phase 2 study of Alzheimer Disease and Dementia that has completed, run by Eli Lilly and Company. The registered enrollment target is 95 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04640077, a Phase 2 study of Alzheimer Disease and Dementia, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over videoconferencing
Conditions Studied
Interventions
- OTHER No Intervention
- DRUG donanemab
Study Locations (20)
Florida
- Bradenton Research Center, Inc. - Bradenton
- Merritt Island Medical Research, LLC - Merritt Island
- Synexus Clinical Research US, Inc. - Orlando
- Advanced Research Consultants - Palm Beach Gardens
- Progressive Medical Research - Port Orange
- Intercoastal Medical Group - Hyde Park - Sarasota
- Stedman Clinical Trials - Tampa
Indiana
- Indiana University - Indianapolis
- Josephson Wallack Munshower Neurology, PC - Indianapolis
Kansas
- The University of Kansas - Clinical Research Center - Fairway
- Cotton O'Neil Clinical Research Center - Central Office - Topeka
Ohio
- Ohio State University - Columbus
- Neurology Diagnostics, Inc. - Dayton
Arizona
- Banner Alzheimer's Institute - Phoenix
California
- UC Irvine-Institute for Memory Impairments and Neurological Disorders (UCI MIND) - Irvine
Massachusetts
- Boston Center for Memory - Newton
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04640077
The ClinicalTrials.gov registry entry for NCT04640077 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which No Intervention is the first listed.
NCT04640077 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Indiana, Kansas.
Frequently Asked Questions
What is clinical trial NCT04640077 about?
NCT04640077 is a clinical study titled "A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)". The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over videoconferencing
What is the current status of trial NCT04640077?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2020-11-23. Estimated completion is 2024-02-27.
What conditions does trial NCT04640077 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Cognitive Impairment, Central Nervous System Diseases, Brain Diseases.
What interventions are being tested in trial NCT04640077?
The interventions under investigation include: No Intervention (OTHER), donanemab (DRUG).
Who is sponsoring clinical trial NCT04640077?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04640077 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.